Completed PHASE3 NCT00113620

Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy

A Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Dextromethorphan and Quinidine at Two Dose Levels in the Treatment of the Pain of Diabetic Neuropathy

Sponsor: Avanir Pharmaceuticals

Conditions Diabetic Neuropathy Pain

Interventions Neurodex

Updated 6 times since 2017 Last updated: Jul 13, 2016 Started: Jul 31, 2005 Primary completion: Feb 28, 2007 Completion: Feb 28, 2007

A PHASE3 clinical study on Diabetic Neuropathy and Pain, this trial is completed. The trial is conducted by Avanir Pharmaceuticals and has accumulated 6 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jul 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Avanir Pharmaceuticals

Data source: Avanir Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Albuquerque, United States , Bensalem, United States , Castro Valley, United States , Cincinnati, United States , Clearwater, United States , Dallas, United States , DeLand, United States , Evansville, United States , Great Neck, United States and 32 more locations